La Jolla Riquent doesn’t meet endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
La Jolla's lupus agent Riquent (formerly LJP 394) did not statistically significantly increase length of time to renal flare compared to placebo in a preliminary analysis of a 298-patient Phase III trial. Riquent appeared to be well tolerated; patients were treated up to 92 weeks (median of 46 weeks). The estimated median time to renal flare, the primary endpoint, was 123 months on the Riquent arm and 89 months on the placebo arm. Renal flares occurred in 17 (12%) Riquent patients and 24 (16%) placebo patients. "Changes in medical practice may have resulted in fewer renal flares because patients were being treated before a renal flare could have been observed or documented," La Jolla maintains. In a combined analysis of renal and/or major SLE flares, there were 33 (26%) events in Riquent patients and 51 (33%) in placebo patients. Riquent did yield a significant reduction in antibodies to double-stranded DNA, which is its intended pharmacologic effect. The company continues to analyze study result
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.